2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | |
---|---|---|---|---|---|---|---|---|---|---|
Sales - EUR | 2.454 | 1.125 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Total Income - EUR | 2.454 | 1.125 | 0 | 0 | 215 | 0 | 0 | 0 | 0 | 0 |
Total Expenses - EUR | 3.740 | 7.549 | 2.444 | 42 | 3 | 18 | 0 | 0 | 0 | 0 |
Gross Profit/Loss - EUR | -1.286 | -6.424 | -2.444 | -42 | 211 | -18 | 0 | 0 | 0 | 0 |
Net Profit/Loss - EUR | -1.359 | -6.458 | -2.444 | -42 | 205 | -18 | 0 | 0 | 0 | 0 |
Employees | 1 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Check the financial reports for the company - Boboclin S.r.l.
2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | |
---|---|---|---|---|---|---|---|---|---|---|
Fixed Assets | 7.445 | 2.469 | 0 | -42 | -3 | -21 | -21 | -20 | -20 | -20 |
Current Assets | 6.200 | 139 | 37 | 37 | 0 | 0 | 0 | 0 | 0 | 0 |
Inventories | 5.271 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Receivables | 135 | 141 | 37 | 37 | 0 | 0 | 0 | 0 | 0 | 0 |
Cash | 795 | -1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Shareholders Funds | -30.147 | -41.852 | -43.869 | -43.168 | -42.171 | -41.372 | -40.588 | -39.688 | -39.811 | -39.690 |
Social Capital | 1.116 | 1.125 | 1.113 | 1.095 | 1.074 | 1.054 | 1.034 | 1.011 | 1.014 | 1.011 |
Debts | 43.793 | 44.460 | 43.906 | 43.163 | 42.168 | 41.351 | 40.567 | 39.668 | 39.791 | 39.670 |
Income in Advance | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Exchange rate - RON | 4.9465 | 4.9315 | 4.9468 | 4.8371 | 4.7454 | 4.6535 | 4.5681 | 4.4908 | 4.445 | 4.4821 |
Main CAEN | "8121 - 8121" | |||||||||
CAEN Financial Year |
8122
|
Subscriptions Financial Reports
You can check the financial situation of the companies in relation to the industry of which it is a part, credit limits and the risk of insolvency and suspension of accounts.
Comments - Boboclin S.r.l.